care device
innovative diagnostics device
multiplex analysis
MRSA FRIZ
new diagnostic device
Innovative Molecular Diagnostics point
number of biomarkers
number of deaths
phase
number of infections
multicentric validation study
sequence signatures
developing Multiplex-PCR
Current diagnostics platforms
health care systems
European market potential
European patients
screening of MRSA
safe handling
new system
interviewing end-users
Key market
sequence area
feasibility study
efficient multiplex nucleic acid testing
disposable microfluidic cartridge format
negative impact
integrated semiconductor
multiplexing
optimized workflow
microarrays
sensitive detection
broad range
high complexity
PoC-Cycle
general approach
sensitivity
usability
hospitals
acceptance
missing process-robustness
sample collection
pathogens
routine administration
diagnosis
revised version
future business opportunities
possible variations
pilot production
tests
HPV
combination of accuracy
freedom
addition
Main users
yearly turnover
reliable results
tuberculosis
Experts
appropriate partner
project